anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an activation factor for improving bacteria gene expression, which is mainly used for improving a target product in a bacteria genome. The activation factor gene is separated from the chromatin DNA of Comamonas testosteroni gram negative bacteria, and the gene contains 564bp. Firstly, the tac promoter DNA fragment of 280bp is cloned to the BamHI restriction enzyme cutting site of a plasmid pK18, an activation factor gene protein of 564bp is inserted into the downstream position of the tac promoter so as to build a plasmid pKtac-act5. The pKtac-act5 contains a kanamycin resistant gene and can be copied in most of gram negative bacteria. The plasmid pKtac-act5 can improve the bacteria gene expression. The expression level of the target product of the engineering bacteria is improved by 5-50 times. The plasmid pKtac-act5 can effectively improve the capability of microorganism to decompose harmful substances and is used for biotechnology pharmacy. The plasmid pKtac-act5 also can effectively improve the paraffin liquefaction capability of petroleum cracking flora so as to improve petroleum yield.
Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Medial temporal lobe atrophy (MTA) is a diagnostic marker for mild cognitive impairment (MCI) and Alzheimer's disease (AD), but the accuracy of quantitative MTA (QMTA) in diagnosing early AD is unclear. This study aimed to investigate the accuracy of QMTA and its related components (inferior lateral ventricle [ILV] and hippocampus) with MTA in the early diagnosis of MCI and AD.
METHODS: This study included four groups: normal (NC), MCI stable (MCIs), MCI converted to AD (MCIs), and mild AD (M-AD) groups. Magnetic resonance image analysis software was used to quantify the hippocampus, ILV, and QMTA. MTA was rated by two experienced neurologists. Receiver operating characteristic area under the curve (AUC) analysis was performed to compare their capability in differentiating AD from NC and MCI, and optimal thresholds were determined using the Youden index.
RESULTS: QMTA distinguished M-AD from NC and MCI with higher diagnostic accuracy than MTA, hippocampus, and ILV (AUCNC = 0.976, AUCMCI = 0.836, AUCMCIs = 0.894, AUCMCIc = 0.730). The diagnostic accuracy of QMTA was superior to that of MTA, the hippocampus, and ILV in differentiating MCI from AD. The diagnostic accuracy of QMTA was found to remain the best across age, sex, and pathological subgroups analyzed. The sensitivity (92.45%) and specificity (90.64%) were higher in this study when a cutoff value of 0.635 was chosen for QMTA.
CONCLUSIONS: QMTA may be a better choice than the MTA scale or the associated quantitative components alone in identifying AD patients and MCI individuals with higher progression risk.
Includes participants with human epidermal growth factor receptor 2 positive (HER2+). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
Participants in Arm 2 will receive a placebo vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
This is an observational cohort study building on an existing protocol at our institution recruiting CF patients who are 6-21 years old with one or two copies of the F508del CFTR mutation. The existing protocol is funded by the NHLBI under R01-11863962 (PIs Woods, Clancy, and hereafter referred to as "the NHLBI study" for simplicity), and seeks to enroll a total of 38 subjects; it includes three to four (three scheduled, with a fourth optional) study visits, with spirometry, LCI, UTE MRI, and 129Xe MRI being performed at each visit. This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits. The target enrollment is 20 subjects.

Airway clearance therapy (ACT) is used for treating cystic fibrosis (CF). It is known to impact measures of lung function, and while an increasing number of lung function measures are used in clinical trials, there has been no direct comparison of the effects of ACT across the different modalities. This study is actively investigating the relationship between different measures of lung function, comparing a spirometric measure (FEV1 percent-predicted) with measures of whole-lung ventilation (lung clearance index, or LCI) and regional assessments of both structure (with ultra-short echo time magnetic resonance imaging, or UTE MRI) and function (with hyperpolarized xenon, or 129Xe, MRI). Performing these assessments on CF patients will help to elucidate the relative sensitivity of each measure to intra-individual changes within the lung and will help guide the selection of lung function measures in future studies.
Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.
PROBLEM TO BE SOLVED: To provide a stable emulsion which contains a high-mol.-wt. polyorganosiloxane in a high concn. and hardly pollutes the environment when used and to provide a cosmetic contg. the same. SOLUTION: This polyorganosiloxane emulsion is prepd. by the emulsion polymn. of a silanol-terminated polydiorganosiloxane having a viscosity of 10-3,000 cSt in the presence of an alkylbenzenesulfonic acid and an alkylsulfuric acid. The objective cosmetic contains the emulsion.
Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
Wait-list control group. Individuals in this group will complete baseline, mid-, and post-treatment assessments before receiving the intervention (i.e., 4 weeks after randomization).
It is now known that ethnic minorities are less likely to receive quality health services and evidence worse treatment outcomes when compared with other groups (IOM, 1999; USDHHS, 2001). Moreover, there continues to be a shortage of systematic investigations examining the efficacy of evidence-based treatments (EBTs) with ethnic minorities, especially among Chinese Americans. Developing interventions that are both empirically grounded and that are culturally sensitive and compatible with Chinese culture is one promising strategy that may improve treatment outcomes for this understudied group. The goal of this study is to culturally adapt a cognitive-behavioral therapy manual for use with depressed Chinese American patients. This study will be among the first to develop a culturally adapted EBT for use with this ethnic group and will involve three study phases. Phase I of the study will focus on modifying and refining a CBT intervention protocol into a manualized treatment for Chinese Americans. Phase two involves a randomized controlled trial (RCT) comparing the effects of the culturally adapted CBT treatment manual with nonadapted CBT. Phase three will involve further refinement of the treatment manual, data analysis, and report writing. Patients will be recruited from an ethnic-specific mental health center that specializes in treating Asian American clientele to participate in the study. Patients will be randomly assigned to either the adapted CBT treatment or the nonadapted CBT treatment. Moreover, feedback from patients and therapists in both conditions will be used to further refine the new treatment manual, provide valuable information about salient issues in treating depressed Chinese Americans, and will provide initial estimates of treatment parameters that will be used in preparing a larger R01 proposal to further test the adapted intervention.
Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations "Coping with stress during the 2019 nCoV outbreak". Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'.
The invention relates to a cefamandole nafate compound and a pharmaceutical composition of the cefamandole nafate compound. The cefamandole nafate compound is crystal, and is determined by X-ray powder diffraction, and the characteristic peak in an atlas is shown as 8.8 degrees, 9.5 degrees, 10.2 degrees, 11.3 degrees, 12.0 degrees, 14.4 degrees, 16.8 degrees, 17.3 degrees, 20.6 degrees, 25.0 degrees, 27.8 degrees, 28.1 degrees and 30.2 degrees in a range of 20+/0.2 degrees. The pharmaceutical composition of the cefamandole nafate compound is a preparation and a pharmaceutical composition preparation containing the above cefamandole nafate compound and the preparation is powder-injection. The cefamandole nafate crystalline compound is high in stability and few in insoluble particles; a cosolvent is not needed, so that the compound can be directly and aseptically sub-packaged to obtain cefamandole nafate powder injection for injection. The cefamandole nafate crystalline compound is also fully mixed with aseptic sodium carbonate powder to be aseptically sub-packaged. The number of insoluble particles added with the powder injection of sodium carbonate is few on the basis of reaching standard request.
Olfactory dysfunction is a common feature of both postviral upper respiratory tract infections (PV) and idiopathic Parkinson's disease (PD). Our aim was to investigate potential differences in the connectivity of the posterior piriform cortex, a major component of the olfactory cortex, between PV and PD patients. Fifteen healthy controls (median age 66 years, 9 men), 15 PV (median age 63 years, 7 men) and 14 PD patients (median age 70 years, 9 men) were examined with task-based olfactory fMRI, including two odors: peach and fish. fMRI data were analyzed with the co-activation pattern (CAP) toolbox, which allows a dynamic temporal assessment of posterior piriform cortex (PPC) connectivity. CAP analysis revealed 2 distinct brain networks interacting with the PPC. The first network included regions related to emotion recognition and attention, such as the anterior cingulate and the middle frontal gyri. The occurrences of this network were significantly fewer in PD patients compared to healthy controls (p = 0.023), with no significant differences among PV patients and the other groups. The second network revealed a dissociation between the olfactory cortex (piriform and entorhinal cortices), the anterior cingulate gyrus and the middle frontal gyri. This second network was significantly more active during the latter part of the stimulation, across all groups, possibly due to habituation. Our study shows how the PPC interacts with areas that regulate higher order processing and how this network is substantially affected in PD. Our findings also suggest that olfactory habituation is independent of disease.
PROBLEM TO BE SOLVED: To provide an effective vaccine to confer protection against a variety of viruses that result in respiratory tract infection.SOLUTION: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. In particular, the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by the nucleotide sequences.
PURPOSE:To obtain a medical cataplasm capable of readily adhering to a human body and free from moving and squeezing by laminating plural tacky adhesive layers on a backing support while inserting an intermediate sheet having releasing property on the both surfaces and each containing a crosslinking reaction component in one of the tacky adhesive layers and crosslinking components in the remainder. CONSTITUTION:The first tacky adhesive layer 2 (e.g. polymer consisting of 82mol octyl acrylate, 8mol butyl methacrylate and 10mol methacrylic acid and having 460000 weight average molecular weight), and the second tacky adhesive layer 4 containing an intermediate sheet 3 having release property on the both surface and crosslinking component (e.g. zinc octylate) for the first tacky agent layer are successively laminated and further protecting sheet 5 is laminated thereon. The protecting sheet 5 having release property is released from the tacky adhesive layer 4 and the intermediate sheet 3 is released while putting the tacky adhesive layer 4 thereon and turned upside down and the tacky adhesive layer 4 is bonded to the tacky adhesive layer 2 and the intermediate sheet 3 is released the exposed surface of the tacky adhesive layer 4 is pressed and applied upon an appointed part of skin. A medicine is contained in at least one layer of tacky adhesive layers 2 and 4.
The present invention relates to the field of medical health care products, and disclosed are an Achyranthes bidentata Blume stem and/or leaf and/or root extract, an extraction method, and application. The extract is Achyranthes bidentata polysaeeharides, and monosaccharide basic structural units of the Achyranthes bidentata polysaeeharides comprise fructose and glucose. The Achyranthes bidentata polysaeeharides is prepared by purifying the Achyranthes bidentata Blume stem and/or leaf and/or root extract, and a molecular weight range of the Achyranthes bidentata polysaeeharides is 1-3 kD. In the extraction method for the Achyranthes bidentata Blume stem and/or leaf and/or root extract, an extraction agent is alkali water or ethanol. The method of the present invention overcomes the problems that there is a gap in research on Achyranthes bidentata Blume at present and the medicinal value is underdeveloped. Compared with published Achyranthes bidentata polysaeeharides, the Achyranthes bidentata polysaeeharides of the present invention has higher immunologic competence, hypoglycemic activity, and hepatoprotective activity, is conducive to promotion, and can be used for improving the development of immunologic competent, hypoglycemic, and hepatoprotective health care foods and drugs.
The quality of the therapeutic relationship is critical in determining psychotherapy outcomes. However, facilitating patients' self-awareness and reflection on their affective responses to their therapist remains understudied as a potential tool for enhancing this relationship and subsequent treatment outcomes. The primary objective of this study is to examine the influence of a brief post-session battery, designed to foster patient self-monitoring and reflection on their emotional reactions toward their psychotherapist, on the quality of the therapeutic relationship and treatment outcomes. Using an observational randomized control trial design, participants will be allocated into intervention and control groups. Those in the intervention group will complete a postsession battery following each therapy session, while the control group will only undergo regular treatment. Data collection will be facilitated through the Qualtrics online survey software and span baseline, mid-trial (5th week), and end-of-trial (10th week) assessments.
If pain or hematuria should occur during irrigation, it should be discontinued and the patient re-evaluated.

Do not use unless solution is clear, seal is intact and container is undamaged. Discard unused portion.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies with Acetic Acid Irrigation, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Nursing Mothers: Caution should be exercised when Acetic Acid Irrigation, USP is administered to a nursing woman.

Pregnancy: Teratogenic Effects. Pregnancy Category C. Animal reproduction studies have not been conducted with Acetic Acid Irrigation, USP. It is also not known whether Acetic Acid Irrigation, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Acetic Acid Irrigation, USP should be given to a pregnant woman only if clearly needed.

Pediatric Usage: The safety and effectiveness have not been established. Its limited use in pediatric patients has been inadequate to fully define proper dosage and limitations for use.
PCT No. PCT/SE92/00333 Sec. 371 Date Dec. 29, 1993 Sec. 102(e) Date Dec. 29, 1993 PCT Filed May 19, 1992 PCT Pub. No. WO92/21335 PCT Pub. Date Dec. 10, 1992.The invention relates to an emulsion which comprises phospholipids containing omega-3-fatty acids such as DHA and EPA in a high amount and a vegetable oil and/or marine oil. It also relates to the use of phospholipids containing the omega-3-fatty acids such as DHA and EPA in high amount for the manufacturing of a nutritive emulsion giving low serum triglyceride and cholesterol levels and for the manufacturing of a medicament with anti-inflammatory and immunosuppressive effects. The invention also discloses phospholipids containing omega-3-fatty acids such as DHA and EPA with therapeutic effects such as effects on inflammatory and immunologically active cells, e.g. rheumatoid arthritis and sepsis and an effect on normal brain and retina development and function and cardiovascular diseases. Also disclosed are pharmaceutical and nutritive compositions as well as lipid particles comprising the phospholipids.
Ammonia and microcystin-LR (MC-LR) are both toxins that can be in eutrophic waters during cyanobacterial blooms. While previous studies have focused on the effects of ammonia exposure on fish neurobehavioral toxicity, little attention has been given to the effects of MC-LR and combined exposures to both. This study exposed adult female zebrafish to ammonia (30 mg/L) and MC-LR (10 μg/L) alone and in combination for 30 days to investigate their neurotoxic effects and underlying mechanisms. Behavioral results showed that exposure to ammonia and MC-LR, both alone and in combination, led to decreased locomotor activity and increased anxiety in fish. Histomorphological analysis revealed the formation of thrombi and vacuolization in the brain across all exposure groups. Exposure to ammonia and MC-LR resulted in significant increases in MDA contents, decreases in Mn-SOD activities, and alterations in GSH contents compared to the control. Single and combined exposure to ammonia and MC-LR also induced the release of inflammatory factors (IL-1β and TNF-α) by activating the NOD/NF-κB signaling pathway. Furthermore, both ammonia and MC-LR significantly changed the expression of genes related to the glutamatergic and GABAergic systems, elevated Glu and GABA contents, as well as increased the Glu/GABA ratio, indicating that a shift towards increased Glu levels. Overall, these findings suggested that exposure to MC-LR and ammonia, individually and in combination, could decrease locomotor activity and increase anxiety of female zebrafish. This was likely due to brain damage from over-activated ROS and the release of pro-inflammatory cytokines, which led to a disruption in the balance of glutamatergic and GABAergic systems. However, there was no significant interaction between MC-LR and ammonia in fish neurobehavioral toxicity.
Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, overexpression of GLDC in NIH/3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.
Initial studies indicated that approximately 60 days after the first COVID-19 symptom onset, only 13% of patients previously hospitalized for COVID-19 were reported to be essentially free of any COVID-19-related symptoms, while 32% had one or two symptoms and 55% had three or more symptoms. Furthermore, the COVID-19 pandemic gives rise to new psychosocial and emotional stressors for recovering patients, including social isolation, physical distancing, loss of employment and uncertainties about the future. In the confrontation of such an uncertain prognosis, it seems justified to introduce preventive actions against the development of pandemic-related adverse effects. To date, only few publications assessed the effectiveness of early post-hospital rehabilitation of patients with COVID-19. This project is aimed to propose an innovative comprehensive intervention based on a stationary pulmonary rehabilitation (PR) programme for COVID-19 survivors. Moreover, this project assumes the use of virtual reality (VR) in rehabilitation processes.
The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.